Drug Trial Radar · NCT06441630
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
Last checked: Nov 19, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
251
Planned (sponsor's estimate)
Start
Jul 31, 2024
Primary completion
Sep 2025
Study completion Sep 2025
Sponsor
- Lead sponsor
- Addpharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
Conditions
- Essential Hypertension
Interventions
AD-227ADrug
Per Oral, 1 Tablet, Once a day for 8 weeks
AD-227BDrug
Per Oral, 1 Tablet, Once a day for 8 weeks
AD-227CDrug
Per Oral, 1 Tablet, Once a day for 8 weeks
Placebo of AD-227BDrug
Per Oral, 1 Tablet, Once a day for 8 weeks
Placebo of AD-227CDrug
Per Oral, 1 Tablet, Once a day for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in MSSBPTime frame: Baseline to Week8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gangnam CHA Medical Center
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.